Lyon, France, January 18, 2022 – Inova, a leading platform in the world of partnering for biopharmaceutical players, completes the acquisition of Labiotech, the leading media dedicated to biotechnology in Europe. This acquisition follows the €60 million investment made in 2021 by international investment firm The Carlyle Group (NASDAQ: CG) and the renewal of support from NextStage AM. This operation will allow Inova to offer an innovative and unique service to biotechs, universities and pharmaceutical companies around the world.
Inova supports through its solutions more than 150 customers worldwide, including most of the largest pharmaceutical companies. The company is today at the forefront of digital transformations for the collaboration of biopharmaceutical players. Inova's flagship product, 'Inova Enterprise', is a collaborative tool that manages all potential partnerships related to innovations outsourced to laboratories and biotechs, allowing its customers to generate, prospect, execute transactions, build alliances and organize virtual events.
Labiotech.eu is the leading information site on the biotechnology sector in Europe. Launched in 2014, it is viewed by over 100 industry professionals each month and plays a vital role in the industry as a trusted source of information and analysis. The quality, journalistic independence and accessibility to information provided by Labiotech.eu allow professionals in the sector to stay informed and collaborate more easily.
Through this acquisition, Inova and Labiotech will partner to provide the industry with a single space that will connect key players from all sides, stay informed of important updates and manage their partnering processes at a single point. and same place. Labiotech will retain its editorial independence in the selection and production of its news, but its founder and chief executive, Joachim Eeckhout, will report to Inova's chief strategy officer, Caroline Toulemonde.
“We are delighted to welcome Labiotech to the Inova community and we are very excited for the coming year. This partnership will make it possible to expand the offers for each of the two parties. We believe that access to information and knowledge sharing are key issues in a technology-driven industry. This association will provide European scientists with a platform to exchange and establish partnerships with leading pharmaceutical companies and investors worldwide. We are building a digital bridge for innovation in science.” said Gilles Toulemonde, founder and CEO of Inova.
“We founded Labiotech.eu to fill the information gap in the European biotech industry and this acquisition gives us the support we need to go even further in our mission. Labiotech and Inova are two sides of the same coin. On the one hand, Labiotech provides information allowing biotechnology and pharmaceutical companies to get to know each other better and to follow trends in the sector. On the other hand, Inova helps them to meet and organize innovation together thanks to its software/IT solutions. The marriage of a media and a SaaS is always a source of interesting synergies, and our example which will be applied to the life sciences is a first in the industry. Over the past seven years, we have been in a unique position to connect biotechnology and biopharma professionals to make them more informed and more successful, and I look forward to leading our team into the next chapter of our history.”, said Joachim Eeckhout, founder and CEO of Labiotech.eu.
About Inova
Inova is a cloud-based solution designed to help science-based companies more effectively identify and manage their biopharmaceutical opportunities. It offers a platform for organizing events, obtaining licenses, partnering opportunities, concluding agreements and alliances. Inova has more than 125 employees distributed between its headquarters in Lyon, France, and its offices in New York, Denver and Tokyo. More information is available on Inova.io.
Follow Inova on LinkedIn and Twitter.
About Labiotech
Labiotech is the publishing company of www.labiotech.eu., the main information site on biotechnology in Europe. Labiotech has 6 employees and is headquartered in Berlin, Germany.
Follow Labiotech on LinkedIn and Twitter.
Press contacts:
Innovates
Sarah Issa
+33 6 24 86 81 69
sarah.issa@inova.io
labiotech
Joachim Eeckout
+49 157 53040778
joachim@labiotech.eu
